Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,848.19 -28.86 (-0.37%) Bitcoin USD
64,839.05 +2,427.68 (+3.89%) CMC Crypto 200
1,331.43 +18.81 (+1.45%)
Moderna, Inc. (MRNA)
| Previous close | 102.00 |
| Open | 102.37 |
| Bid | 102.55 x 300 |
| Ask | 103.04 x 300 |
| Day's range | 102.06 - 103.79 |
| 52-week range | 62.55 - 142.82 |
| Volume | |
| Avg. volume | 3,775,035 |
| Market cap | 39.36B |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.33 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 132.36 |
- Reuters
FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
ZacksModerna (MRNA) Stock Moves -0.34%: What You Should Know
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.
FortuneHow Moderna’s CIO helps steer the drugmaker’s post-COVID evolution
Brad Miller is helping Moderna shift from its reliance on COVID vaccines, with the company hoping to introduce up to 15 new drugs over a five-year period.
